219 related articles for article (PubMed ID: 16189072)
1. Effect of ribavirin on intracellular and plasma pharmacokinetics of nucleoside reverse transcriptase inhibitors in patients with human immunodeficiency virus-hepatitis C virus coinfection: results of a randomized clinical study.
Rodriguez-Torres M; Torriani FJ; Soriano V; Borucki MJ; Lissen E; Sulkowski M; Dieterich D; Wang K; Gries JM; Hoggard PG; Back D
Antimicrob Agents Chemother; 2005 Oct; 49(10):3997-4008. PubMed ID: 16189072
[TBL] [Abstract][Full Text] [Related]
2. Intracellular nucleoside triphosphate concentrations in HIV-infected patients on dual nucleoside reverse transcriptase inhibitor therapy.
Moore JD; Acosta EP; Johnson VA; Bassett R; Eron JJ; Fischl MA; Long MC; Kuritzkes DR; Sommadossi JP
Antivir Ther; 2007; 12(6):981-6. PubMed ID: 17926654
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetic evaluation of the effects of ribavirin on zidovudine triphosphate formation: ACTG 5092s Study Team.
Aweeka FT; Kang M; Yu JY; Lizak P; Alston B; Chung RT;
HIV Med; 2007 Jul; 8(5):288-94. PubMed ID: 17561874
[TBL] [Abstract][Full Text] [Related]
4. Peginterferon alfa-2a plus ribavirin for HIV-HCV genotype 1 coinfected patients: a randomized international trial.
Rodriguez-Torres M; Slim J; Bhatti L; Sterling R; Sulkowski M; Hassanein T; Serrão R; Sola R; Bertasso A; Passe And S; Stancic S
HIV Clin Trials; 2012; 13(3):142-52. PubMed ID: 22592094
[TBL] [Abstract][Full Text] [Related]
5. A comparison of the steady-state pharmacokinetics and safety of abacavir, lamivudine, and zidovudine taken as a triple combination tablet and as abacavir plus a lamivudine-zidovudine double combination tablet by HIV-1-infected adults.
Crémieux AC; Katlama C; Gillotin C; Demarles D; Yuen GJ; Raffi F;
Pharmacotherapy; 2001 Apr; 21(4):424-30. PubMed ID: 11310515
[TBL] [Abstract][Full Text] [Related]
6. Simultaneous quantitation of the 5'-triphosphate metabolites of zidovudine, lamivudine, and stavudine in peripheral mononuclear blood cells of HIV infected patients by high-performance liquid chromatography tandem mass spectrometry.
Moore JD; Valette G; Darque A; Zhou XJ; Sommadossi JP
J Am Soc Mass Spectrom; 2000 Dec; 11(12):1134-43. PubMed ID: 11118121
[TBL] [Abstract][Full Text] [Related]
7. Effect of an induction period of pegylated interferon-α2a and ribavirin on early virological response in HIV-HCV-coinfected patients: results from the CORAL-2 study.
Tural C; Solà R; Alvarez NP; Moltó J; Sánchez M; Zamora AM; Ornelas A; Laguno M; González J; von Wichmann MÁ; Téllez MJ; Paredes R; Clotet B;
Antivir Ther; 2011; 16(6):833-41. PubMed ID: 21900715
[TBL] [Abstract][Full Text] [Related]
8. Role of pegylated interferon-alpha-2a and ribavirin concentrations in sustained viral response in HCV/HIV-coinfected patients.
Lopez-Cortes LF; Valera-Bestard B; Gutierrez-Valencia A; Ruiz-Valderas R; Jimenez L; Arizcorreta A; Terrón A; Viciana P
Clin Pharmacol Ther; 2008 Nov; 84(5):573-80. PubMed ID: 18596682
[TBL] [Abstract][Full Text] [Related]
9. Correlation between intracellular pharmacological activation of nucleoside analogues and HIV suppression in vitro.
Hoggard PG; Sales SD; Kewn S; Sunderland D; Khoo SH; Hart CA; Back DJ
Antivir Chem Chemother; 2000 Nov; 11(6):353-8. PubMed ID: 11227992
[TBL] [Abstract][Full Text] [Related]
10. Comparison of high ribavirin induction versus standard ribavirin dosing, plus peginterferon-α for the treatment of chronic hepatitis C in HIV-infected patients: the PERICO trial.
Labarga P; Barreiro P; da Silva A; Guardiola JM; Rubio R; Aguirrebengoa K; Miralles P; Portu J; Téllez MJ; Morano L; Castro A; Pineda JA; Terrón A; Hernández-Quero J; Mariño A; Ríos MJ; Echeverría S; Asensi V; Vispo E; Soriano V;
J Infect Dis; 2012 Sep; 206(6):961-8. PubMed ID: 22807523
[TBL] [Abstract][Full Text] [Related]
11. Low Efficacy of Pegylated Interferon plus Ribavirin plus Nitazoxanide for HCV Genotype 4 and HIV Coinfection.
Macías J; López-Cortés LF; Téllez F; Recio E; Ojeda-Burgos G; Ríos MJ; Rivero-Juárez A; Delgado M; Rivas-Jeremías ; Pineda JA
PLoS One; 2015; 10(12):e0143492. PubMed ID: 26640956
[TBL] [Abstract][Full Text] [Related]
12. Distinct hepatitis C virus kinetics in HIV-infected patients treated with ribavirin plus either pegylated interferon alpha2a or alpha2b.
Vispo E; Barreiro P; Rodriguez-Nóvoa S; Morello J; Labarga P; Martín-Carbonero L; Maida I; García-Gascó P; Soriano V
Antivir Ther; 2008; 13(4):511-7. PubMed ID: 18672529
[TBL] [Abstract][Full Text] [Related]
13. Effect of abacavir on sustained virologic response to HCV treatment in HIV/HCV co-infected patients, Cohere in Eurocoord.
; Smit C; Arends J; Peters L; Montforte Ad; Dabis F; Zangerle R; Daikos G; Mussini C; Mallolas J; de Wit S; Zinkernagel A; Cosin J; Chene G; Raben D; Rockstroh J
BMC Infect Dis; 2015 Nov; 15():498. PubMed ID: 26537918
[TBL] [Abstract][Full Text] [Related]
14. Relative impact of ribavirin monitoring and HIV coinfection on sustained virological response in patients with chronic hepatitis C.
Piedoux S; Monnet E; Piroth L; Montange D; Royer B; Thevenot T; Kantelip JP; Di Martino V; Muret P;
Antivir Ther; 2011; 16(8):1317-26. PubMed ID: 22155913
[TBL] [Abstract][Full Text] [Related]
15. Critical role of ribavirin for the achievement of early virological response to HCV therapy in HCV/HIV-coinfected patients.
Ramos B; Núñez M; Rendón A; Berdún MA; Losada E; Santos I; Echevarría S; Ocampo A; Miralles C; Arazo P; Barreiro P; Romero M; Labarga P; Guardiola JM; Garcia-Samaniego J; Soriano V
J Viral Hepat; 2007 Jun; 14(6):387-91. PubMed ID: 17501758
[TBL] [Abstract][Full Text] [Related]
16. Zidovudine use but not weight-based ribavirin dosing impacts anaemia during HCV treatment in HIV-infected persons.
Alvarez D; Dieterich DT; Brau N; Moorehead L; Ball L; Sulkowski MS
J Viral Hepat; 2006 Oct; 13(10):683-9. PubMed ID: 16970600
[TBL] [Abstract][Full Text] [Related]
17. Influence of concomitant antiretroviral therapy on the rate of sustained virological response to pegylated interferon plus ribavirin in hepatitis C virus/HIV-coinfected patients.
Pineda JA; Mira JA; Gil Ide L; Valera-Bestard B; Rivero A; Merino D; Girón-González JA; Ríos-Villegas MJ; González-Serrano M; Collado A; García-García JA; Carrillo-Gómez R; López-Cortés LF; Gómez-Mateos J
J Antimicrob Chemother; 2007 Dec; 60(6):1347-54. PubMed ID: 17938129
[TBL] [Abstract][Full Text] [Related]
18. Ribavirin Concentrations Do Not Predict Sustained Virological Response in HIV/HCV-Coinfected Patients Treated with Ribavirin and Pegylated Interferon in the Swiss HIV Cohort Study.
Kovari H; Russmann S; Ledergerber B; Müller D; Rotger M; Velli P; Cavassini M; Ambrosioni J; Bregenzer A; Stöckle M; Bernasconi E; Rauch A; Speck RF;
PLoS One; 2015; 10(7):e0133879. PubMed ID: 26218843
[TBL] [Abstract][Full Text] [Related]
19. Mitochondrial effects of a 24-week course of pegylated-interferon plus ribavirin in asymptomatic HCV/HIV co-infected patients on long-term treatment with didanosine, stavudine or both.
Ballesteros AL; Miró O; López S; Fuster D; Videla S; Martínez E; Garrabou G; Salas A; Côté H; Tor J; Rey-Joly C; Planas R; Clotet B; Tural C
Antivir Ther; 2004 Dec; 9(6):969-77. PubMed ID: 15651755
[TBL] [Abstract][Full Text] [Related]
20. Interferon-ribavirin in association with stavudine has no impact on plasma human immunodeficiency virus (HIV) type 1 level in patients coinfected with HIV and hepatitis C virus: a CORIST-ANRS HC1 trial.
Salmon-Céron D; Lassalle R; Pruvost A; Benech H; Bouvier-Alias M; Payan C; Goujard C; Bonnet E; Zoulim F; Morlat P; Sogni P; Pérusat S; Tréluyer JM; Chêne G;
Clin Infect Dis; 2003 May; 36(10):1295-304. PubMed ID: 12746776
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]